Q-omics provides the consensus-scored DUSP5 profile across patient tissues and cancer cell-line models. DUSP5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DUSP5 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, DUSP5 RNA expression shows 17,986 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and THCA as cancer lineages where DUSP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DUSP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DUSP5 survival associations across molecular data types. DUSP5 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DUSP5 RNA expression–survival associations across cancer types. High DUSP5 expression shows unfavorable associations in ACC, UVM, LUAD, LGG and HNSC, but favorable associations in SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DUSP5 RNA expression.
This table summarizes DUSP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DUSP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DUSP5 shows lower tumor expression in KICH, KIRC, BLCA and LIHC and higher tumor expression in THCA and LUAD. The THCA box plot shows higher DUSP5 RNA expression in tumor versus normal tissue (log2 FC = +3.250, t-test p < 0.001).
This table shows molecular features associated with DUSP5 in patient tissues and cancer cell lines. In patient samples, DUSP5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DUSP5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
